JP2532495B2 - Skin cosmetics - Google Patents
Skin cosmeticsInfo
- Publication number
- JP2532495B2 JP2532495B2 JP62196928A JP19692887A JP2532495B2 JP 2532495 B2 JP2532495 B2 JP 2532495B2 JP 62196928 A JP62196928 A JP 62196928A JP 19692887 A JP19692887 A JP 19692887A JP 2532495 B2 JP2532495 B2 JP 2532495B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- estrogen
- vitamin
- glycosaminoglycan
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002537 cosmetic Substances 0.000 title claims description 19
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 19
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 18
- 229940011871 estrogen Drugs 0.000 claims description 18
- 239000000262 estrogen Substances 0.000 claims description 18
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 17
- 235000019155 vitamin A Nutrition 0.000 claims description 17
- 239000011719 vitamin A Substances 0.000 claims description 17
- 229940045997 vitamin a Drugs 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 description 31
- 229920002683 Glycosaminoglycan Polymers 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 12
- 239000006210 lotion Substances 0.000 description 7
- 239000006071 cream Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229920002674 hyaluronan Polymers 0.000 description 5
- 229960003160 hyaluronic acid Drugs 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 5
- 206010016807 Fluid retention Diseases 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 3
- 229960000452 diethylstilbestrol Drugs 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- QXNWZXMBUKUYMD-ITUXNECMSA-N 4-keto-beta-carotene Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C QXNWZXMBUKUYMD-ITUXNECMSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- XWCYDHJOKKGVHC-UHFFFAOYSA-N Vitamin A2 Chemical compound OCC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C XWCYDHJOKKGVHC-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- JNAYPSWVMNJOPQ-UHFFFAOYSA-N 2,3-bis(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C JNAYPSWVMNJOPQ-UHFFFAOYSA-N 0.000 description 1
- -1 2-Octyldodecyl Chemical group 0.000 description 1
- QHNVWXUULMZJKD-UHFFFAOYSA-N 3,4-didehydroretinal Chemical compound O=CC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C QHNVWXUULMZJKD-UHFFFAOYSA-N 0.000 description 1
- PBBGSZCBWVPOOL-HDICACEKSA-N 4-[(1r,2s)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol Chemical compound C1([C@H](CC)[C@H](CC)C=2C=CC(O)=CC=2)=CC=C(O)C=C1 PBBGSZCBWVPOOL-HDICACEKSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- DPRNENKPXAZQBI-UHFFFAOYSA-N alpha-Vitamin A Natural products OCC=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C DPRNENKPXAZQBI-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000019244 cryptoxanthin Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006932 echinenone Nutrition 0.000 description 1
- YXPMCBGFLULSGQ-YHEDCBSUSA-N echinenone Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(=O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C YXPMCBGFLULSGQ-YHEDCBSUSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 229950001996 hexestrol Drugs 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は、皮膚の柔軟性、弾力性および表面状態を著
しく改善する化粧料に関する。さらに詳しく言えば、本
発明は、皮膚に潤いを与え、皮膚の生理機能を向上させ
て皮膚の柔軟性、弾力性および表面状態を著しく改善す
る皮膚化粧料に関するものである。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a cosmetic composition which markedly improves the flexibility, elasticity and surface condition of the skin. More specifically, the present invention relates to a skin cosmetic that moisturizes the skin and improves the physiological function of the skin to remarkably improve the flexibility, elasticity and surface condition of the skin.
皮膚は老化にともない、皮膚の保水機能が低下し、乾
燥し、潤いのないあれ肌となる。その原因として、皮膚
中のグリコサミノグリカンが加齢とともに減少するため
といわれている。As the skin ages, the water retention function of the skin deteriorates and the skin becomes dry and moist. It is said that the cause is that glycosaminoglycan in the skin decreases with age.
これまでの化粧料は、皮膚に不足しているグリコサミ
ノグリカンを配合し、中でも強い保水性を持つヒアルロ
ン酸により皮膚をなめらかにし皮膚に適度な潤いを与え
ようとしてきた(特公昭33-500号、特公昭55-160712
号)。しかし、この外部からの保湿成分の補足では効果
に限界があるので、皮膚内部に働きかけ皮膚の機能を高
めて保湿性を高めるためにヒアルロン酸合成に関与する
生理活性物質を配合していた。例えば真皮のヒアルロン
酸生合成能を高めるエストロゲンを配合した化粧料や、
エストロゲンとグリコサミノグリカンとを組合せて相乗
効果を求めた化粧料(特開昭59-25311号)、また表皮の
ヒアルロン酸生合成能を高めるビタミンAを配合した
り、あるいはグリコサミノグリカンとビタミンAを組合
わせ配合した化粧料(特開昭60-252405号)等の技術が
開示されていた。Until now, cosmetics have blended glycosaminoglycan, which is lacking in the skin, and have tried to moisturize and moisturize the skin with hyaluronic acid, which has a strong water retention property (JP-B-33-500). Issue, Shokoku Sho 55-160712
issue). However, since supplementation of the moisturizing component from the outside has a limited effect, a physiologically active substance involved in hyaluronic acid synthesis has been blended in order to act on the inside of the skin to enhance the function of the skin and enhance the moisturizing property. For example, cosmetics containing estrogen that enhances hyaluronic acid biosynthesis in the dermis,
Cosmetics that seek a synergistic effect by combining estrogen and glycosaminoglycan (Japanese Patent Laid-Open No. 59-25311), blend with vitamin A that enhances hyaluronic acid biosynthesis in the epidermis, or combine glycosaminoglycan Techniques such as cosmetics containing a combination of vitamin A (JP-A-60-252405) have been disclosed.
しかし外部から補充したグリコサミノグリカンは洗顔
や汗などにより簡単に洗い流されてしまうため、グリコ
サミノグリカンのみを配合した化粧料は長期に亘る効果
という点で不十分であった。またエストロゲンやビタミ
ンAは皮膚の内面から働きかけ長期の作用を期待できる
が、エストロゲンは真皮に対する効果が大部分で、エス
トロゲンとグリコサミノグリカンを配合した化粧料では
表皮の状態と密接に関係する皮膚のなめらかさ、皮膚表
面の適度な潤いに効果を与えることはほとんど期待でき
ないし、一方ビタミンAは表皮に対する効果が大部分
で、ビタミンAとグリコサミノグリカンを配合した化粧
料では皮膚の弾力性、皮膚の適度なハリを左右する真皮
への効果はほとんど無いと考えられた。その為、従来の
技術では皮膚組織全体の保水性を高める面で不足であ
り、皮膚の柔軟性、弾力性、保水性の年齢による低下に
対して十分な効果を示さなかった。However, the glycosaminoglycan replenished from the outside is easily washed off by washing the face, sweating, etc., so that the cosmetic containing only glycosaminoglycan was insufficient in terms of long-term effect. Estrogen and Vitamin A work from the inside of the skin and can be expected to have a long-term effect, but estrogen has most of the effect on the dermis, and cosmetics containing estrogen and glycosaminoglycan are closely related to the condition of the epidermis. It can hardly be expected to have an effect on the smoothness and proper moisturization of the skin surface, while vitamin A has the most effect on the epidermis, and cosmetics containing vitamin A and glycosaminoglycan have elasticity on the skin. , It is considered that there is almost no effect on the dermis that influences the proper firmness of the skin. Therefore, the conventional techniques are insufficient in terms of enhancing the water retention of the entire skin tissue, and have not shown sufficient effects on the deterioration of skin flexibility, elasticity and water retention with age.
そこで本発明者らは鋭意研究の結果、表皮のグリコサ
ミノグリカンの生合成能を高め、皮膚になめらかさ、適
度な潤いを与えるビタミンAおよび真皮のグリコサミノ
グリカンの生合成能を高め、肌に弾力性、適度なハリを
与えるエストロゲンを一定量配合した化粧料が、ビタミ
ンA、エストロゲンあるいはグリコサミノグリカン単独
配合や、エストロゲンとグリコサミノグリカンとの組合
わせ、そしてビタミンAとグリコサミノグリカンの組合
わせよりも皮膚の柔軟性、弾性および表面状態を改善す
る効果が大きいことを見い出し本発明を完成するに至っ
た。Therefore, as a result of diligent research, the present inventors have increased the biosynthesis ability of glycosaminoglycans in the epidermis, and have increased the biosynthesis ability of vitamin A and dermis glycosaminoglycans that provide smoothness and appropriate moisturization to the skin Cosmetics containing a certain amount of estrogen that gives elasticity and moderate elasticity to the skin can be formulated with vitamin A, estrogen or glycosaminoglycan alone, a combination of estrogen and glycosaminoglycan, and vitamin A and glycosaminoglycan. The inventors have found that the effect of improving the flexibility, elasticity and surface condition of the skin is greater than the combination of noglycans, and have completed the present invention.
すなわち本発明は、ビタミンA 0.001〜0.01重量%及
びエストロゲン 0.001〜0.01重量%を配合することを特
徴とする皮膚化粧料に関する。That is, the present invention relates to a skin cosmetic characterized by containing 0.001 to 0.01% by weight of vitamin A and 0.001 to 0.01% by weight of estrogen.
以下、本発明を詳細に説明する。 Hereinafter, the present invention will be described in detail.
本発明で用いるエストロゲンは、別名「卵胞ホルモ
ン」と称され、例えばエチニルエストラジオール、17β
−エストラジオール、エストロン、エストリオール、ジ
エチルスチルベストロール、ヘキセストロール等であ
り、これらのうちから1種又は2種以上を任意に選び使
用する。配合量は0.001重量%以上、0.01重量%以下と
する(0.001%未満では効果を発揮しないし、0.01%を
越すと副作用の危険性がある。)。The estrogen used in the present invention is also known as "estrogen", and includes, for example, ethinyl estradiol, 17β.
-Estradiol, estrone, estriol, diethylstilbestrol, hexestrol and the like, and one or more of these are arbitrarily selected and used. The blending amount is 0.001% by weight or more and 0.01% by weight or less (less than 0.001% does not exhibit the effect, and if it exceeds 0.01%, there is a risk of side effects).
本発明で用いるビタミンAは、例えばレチノール、レ
チナール、デヒドロレチノール、デヒドロレチナールお
よびこれらのエステル類あるいはカロチン、リコビン、
ゼアキサンチン、クリプトキサンチン、エキネノン等の
プロビタミン類であり、これらのうちから1種又は2種
以上を任意に選び使用する。配合量は0.001重量%以
上、0.01重量%以下とする(0.001%未満では効果を発
揮しないし、0.01%を越すと副作用の危険性があ
る。)。Vitamin A used in the present invention is, for example, retinol, retinal, dehydroretinol, dehydroretinal and their esters or carotene, lycobin,
These are provitamins such as zeaxanthin, cryptoxanthin, and echinenone, and one or more of these are arbitrarily selected and used. The blending amount is 0.001% by weight or more and 0.01% by weight or less (less than 0.001% does not exhibit the effect, and if it exceeds 0.01%, there is a risk of side effects).
またエストロゲンとビタミンAの比率は1:1/2〜2の
範囲で皮膚に対して有効であり、この比率の範囲で使用
することが好ましい。The ratio of estrogen to vitamin A is effective in the skin in the range of 1: 1/2 to 2, and it is preferable to use it in the range of this ratio.
本発明の皮膚化粧料は前記の必須成分以外に、必要に
応じて本発明の効果を損わない範囲で化粧品、医薬品等
に一般に用いられる各種成分、すなわち水性成分、粉末
成分、油分、界面活性剤、保湿剤、増粘剤、酸化防止
剤、香料、色材、紫外線吸収剤、ビタミン類、薬剤等を
配合できる。また、前項で示したビタミンAとエストロ
ゲンの構成比によって異なるが、状況に応じてビタミン
Aとエストロゲンの効果を補足する意味でグリコサミノ
グリカンを該化粧料に対して0.01%以上10%以下の範囲
で配合することもできる(0.01未満では効果を補足する
のに十分でなく、10%を越すと化粧品剤型上好ましくな
い。)。The skin cosmetics of the present invention include, in addition to the above-mentioned essential components, various components generally used in cosmetics, pharmaceuticals, etc., if necessary, within a range that does not impair the effects of the present invention, that is, an aqueous component, a powder component, an oil component, and a surfactant Agents, moisturizers, thickeners, antioxidants, fragrances, coloring materials, ultraviolet absorbers, vitamins, drugs and the like can be added. Also, depending on the composition ratio of vitamin A and estrogen shown in the preceding paragraph, glycosaminoglycan is added to the cosmetic in an amount of 0.01% or more and 10% or less in order to complement the effects of vitamin A and estrogen depending on the situation. It can be blended in a range (less than 0.01 is not sufficient to supplement the effect, and if it exceeds 10%, it is not preferable in terms of cosmetic dosage form).
尚、ここで用いるグリコサミノグリカンは、例えばヒ
アルロン酸、コンドロイチン硫酸A、コンドロイチン硫
酸B、コンドロイチン硫酸C、ヘプラン等および(また
は)その塩類である。グリコサミノグリカンの塩を形成
する塩基としては水酸化リチウム、水酸化カリウム、水
酸化ナトリウム等の無機塩、トリエタノールアミン等の
有機塩基およびリジン、アルギニン、β−アラニン等の
塩基性アミノ酸等を例示できる。The glycosaminoglycan used here is, for example, hyaluronic acid, chondroitin sulfate A, chondroitin sulfate B, chondroitin sulfate C, heplan, and / or salts thereof. As the base forming the salt of glycosaminoglycan, lithium hydroxide, potassium hydroxide, inorganic salts such as sodium hydroxide, organic bases such as triethanolamine and lysine, arginine, basic amino acids such as β-alanine It can be illustrated.
以下実施例により本発明および本発明の効果について
記述する。The present invention and the effects of the present invention will be described below with reference to examples.
(製法) 成分A(油相部)および成分B(水相部)をそれぞれ
70℃に加熱し完全溶解したのち、油相部を水相部中に混
合し乳化し、熱交換器にて30℃まで冷却し、作成した。 (Manufacturing method) Component A (oil phase part) and component B (water phase part) respectively
After heating to 70 ° C. to completely dissolve, the oil phase part was mixed with the water phase part to emulsify, and cooled to 30 ° C. in a heat exchanger to prepare.
(使用テスト) 本発明の皮膚化粧料の作用効果を、使用テストにより
試験した。使用テストは70名の女性パネラーを各群10名
づつの7群に分け、第1群には実施例1のクリームを、
第2群には比較例1のクリームを、第3群には比較例2
のクリームを、第4群には比較例1のクリームを、第5
群には比較例4のクリームを第6群には比較例5のクリ
ームを、第7群には比較例6のクリームを、それぞれ1
日1回20日間に亘って塗布し、20日後の効果を「肌の弾
力性および適度なハリ」「肌のしっとり感」の2項目に
つき、その有効性を判定した。結果は表−1に示すとお
りである。(Use test) The action effect of the skin cosmetic of the present invention was tested by a use test. In the use test, 70 female panelists were divided into 7 groups of 10 persons in each group, and the cream of Example 1 was used in the first group.
The cream of Comparative Example 1 was used for the second group, and Comparative Example 2 was used for the third group.
The cream of Comparative Example 1 to the 4th group and the 5th
The cream of Comparative Example 4 was applied to the group, the cream of Comparative Example 5 was applied to the sixth group, and the cream of Comparative Example 6 was applied to the seventh group.
It was applied once a day for 20 days, and the effect after 20 days was evaluated for the two items of "skin elasticity and proper firmness" and "skin moist feeling". The results are as shown in Table 1.
(製法) 70℃に保った成分B(水相)に成分A(油相)を70℃
にて加え、ホモミキサーで均一に乳化後冷却する。 (Manufacturing method) Component A (oil phase) is added to component B (water phase) kept at 70 ° C.
And homogenize with a homomixer and then cool.
(使用テスト) 肌あれ症状を自己申告パネラーを70名を7群に分け、
第1群には実施例2の化粧水を、第2群には比較例7の
化粧水を、第3群には比較例8の化粧水を、第4群には
比較例9の化粧水を、第5群には比較例10の化粧水を、
第6群には比較例11の化粧水を、第7群には比較例12の
化粧水をそれぞれ1ヶ月に亘って塗布し、肌あれ改善が
なされたかどうかにつき、その有効性を判定した。結果
は表−2に示すとおり。(Usage test) 70 people with 70 self-reported panelists for skin symptoms,
The first group contains the lotion of Example 2, the second group contains the lotion of Comparative Example 7, the third group contains the lotion of Comparative Example 8, and the fourth group contains the lotion of Comparative Example 9. To the fifth group, the lotion of Comparative Example 10 was added,
The lotion of Comparative Example 11 was applied to the 6th group, and the lotion of Comparative Example 12 was applied to the 7th group for 1 month, and the effectiveness thereof was determined by whether or not skin roughness was improved. The results are shown in Table-2.
これらの結果から明らかなようにビタミンAをエスト
ロゲンを配合した皮膚化粧料は、ビタミンAまたはエス
トロゲン単独配合、あるいはビタミンAとグリコサミノ
グリカンの組合わせ配合、エストロゲンとグリコサミノ
グリカンの組合わせ配合時よりも肌に「弾力性」「しっ
とり感」が著しく増強され「肌あれが改善された」とい
う効果が確認された。 As is clear from these results, the skin cosmetics containing vitamin A and estrogen are vitamin A or estrogen alone, a combination of vitamin A and glycosaminoglycan, a combination of estrogen and glycosaminoglycan. It was confirmed that the "elasticity" and "moisturizing feeling" were remarkably enhanced on the skin rather than the time, and "the rough skin was improved".
更に実施例を以下に記載する。 Further examples are described below.
実施例3 ファンデーション 疎水性化微粒子酸化チタン 7.0 イソステアリン酸トリグリセライド 2.0 2−オクチルドデシルオレート 8.0 流動パラフィン 3.0 セチルアルコール 5.0 キァンデリラワックス 2.0 POE(25)モノステアレート 2.0 ソルビタンモノステアレート 1.0 黄酸化鉄 1.3 弁柄 0.8 ポリエチレングリコール 4.0 メチルパラベン 0.2 ヒアルロン酸ナトリウム 0.5 香料 0.2 ジエチルスチルベストロール 0.002 レチナール 0.002 精製水 残余 実施例4 パック ポリビニルアルコール 20.0 エタノール 20.0 ヒアルロン酸ナトリウム 0.2 グリセリン 5.0 香料 0.3 エチニルエストラジオール 0.004 レチナール 0.004 精製水 残余 実施例5 オイル スクワラン 47.0 ヒマシ油 47.0 ジエチルスチルベストロール 0.005 レチナール 0.005 精製水 残余Example 3 Foundation Hydrophobized Fine Particle Titanium Oxide 7.0 Isostearic Acid Triglyceride 2.0 2-Octyldodecyl Olate 8.0 Liquid Paraffin 3.0 Cetyl Alcohol 5.0 Candelilla Wax 2.0 POE (25) Monostearate 2.0 Sorbitan Monostearate 1.0 Yellow Iron Oxide 1.3 Valve Pattern 0.8 Polyethylene glycol 4.0 Methylparaben 0.2 Sodium hyaluronate 0.5 Fragrance 0.2 Diethylstilbestrol 0.002 Retinal 0.002 Purified water Residual Example 4 Packed polyvinyl alcohol 20.0 Ethanol 20.0 Hyaluronate 0.2 Glycerin 5.0 Fragrance 0.3 Ethinyl estradiol 0.004 Retinal 0.004 Purified water Residual example 5 Oil Squalane 47.0 Castor oil 47.0 Diethylstilbestrol 0.005 Retinal 0.005 Purified water Residual
Claims (1)
ロゲン 0.001〜0.01重量%を配合することを特徴とする
皮膚化粧料1. A skin cosmetic composition comprising 0.001 to 0.01% by weight of vitamin A and 0.001 to 0.01% by weight of estrogen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62196928A JP2532495B2 (en) | 1987-08-06 | 1987-08-06 | Skin cosmetics |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62196928A JP2532495B2 (en) | 1987-08-06 | 1987-08-06 | Skin cosmetics |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6440412A JPS6440412A (en) | 1989-02-10 |
JP2532495B2 true JP2532495B2 (en) | 1996-09-11 |
Family
ID=16365996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62196928A Expired - Lifetime JP2532495B2 (en) | 1987-08-06 | 1987-08-06 | Skin cosmetics |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2532495B2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5565207A (en) * | 1990-09-19 | 1996-10-15 | Pola Kasei Kogyo Kabushiki Kaisha | Scalp moisturizer and external skin preparation |
JP2931708B2 (en) * | 1991-07-18 | 1999-08-09 | ポーラ化成工業株式会社 | Hair restoration |
JPH0632722A (en) * | 1992-07-13 | 1994-02-08 | Shiseido Co Ltd | External preparation for skin |
DE60028071T2 (en) * | 1999-11-16 | 2006-11-02 | Unilever N.V. | COSMETIC AGENTS CONTAINING PEPPER EXTRACT AND RETINOIDS |
FR2865651B1 (en) | 2004-01-29 | 2007-09-28 | Fabre Pierre Dermo Cosmetique | TOPICAL COMPOSITIONS COMPRISING SODIUM HYALURONATE FRAGMENTS AND RETINOID USEFUL IN COSMETIC AND MEDICAL DERMATOLOGY |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5925311A (en) * | 1982-07-29 | 1984-02-09 | Shiseido Co Ltd | Cosmetic |
JPS61251606A (en) * | 1985-04-30 | 1986-11-08 | Shiseido Co Ltd | Cosmetic |
JPS62411A (en) * | 1985-06-25 | 1987-01-06 | Shiseido Co Ltd | Cosmetic |
-
1987
- 1987-08-06 JP JP62196928A patent/JP2532495B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPS6440412A (en) | 1989-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5093998B2 (en) | Pigmentation preventing or improving agent | |
JP4670366B2 (en) | Skin cosmetics | |
US5153230A (en) | Topical skin cream composition | |
JP3657395B2 (en) | Composition for external use | |
JP5766258B2 (en) | Pigmentation preventing or improving agent | |
JP3432848B2 (en) | Hair restorer | |
DE10033717A1 (en) | Cosmetic and dermatological preparation for removing sebum | |
JP2761939B2 (en) | Oil-in-water emulsion cosmetic | |
JP2002193755A (en) | Antidandruff and anti-itching hair cosmetic and hair- shampooing cosmetic | |
JP3513872B2 (en) | External preparation for skin | |
JPH09221410A (en) | Aging preventing skin ointment | |
JP2532495B2 (en) | Skin cosmetics | |
JPH09183718A (en) | Composition suitable for external application | |
JP2006321758A (en) | Cosmetic | |
JPH0420883B2 (en) | ||
JP4828077B2 (en) | Topical skin preparation | |
JPS60116618A (en) | Cosmetic | |
JP2010189368A (en) | Liquid external preparation for skin | |
JP3104938B2 (en) | Cosmetics | |
JPH07215839A (en) | Skin external agent | |
JP2002275027A (en) | Cosmetic and cosmetic impregnated in nonwoven fabric | |
JP3556479B2 (en) | Skin pre-treatment agent | |
JPH10279427A (en) | Moisture-retaining cosmetic material composition | |
JP2522803B2 (en) | Cosmetics | |
JPH0899861A (en) | Skin external agent |